An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

PURPOSE: To evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab. EXPERIMENTAL DESIGN: PD-L1/PD-1 inhibitor naïve patients with advanced microsatellite stable colo...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Kirsty, Loo Yau, Helen, Chakravarthy, Ankur, Wang, Ben, Shen, Shu Yi, Ettayebi, Ilias, Ishak, Charles A, Bedard, Philippe L, Abdul Razak, Albiruni, R Hansen, Aaron, Spreafico, Anna, Cescon, Dave, Butler, Marcus O, Oza, Amit M, Lheureux, Stephanie, Stjepanovic, Neda, Van As, Brendan, Boross-Harmer, Sarah, Wang, Lisa, Pugh, Trevor J, Ohashi, Pamela S, Siu, Lillian L, De Carvalho, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406114/
https://www.ncbi.nlm.nih.gov/pubmed/32753546
http://dx.doi.org/10.1136/jitc-2020-000883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406114/
https://www.ncbi.nlm.nih.gov/pubmed/32753546
http://dx.doi.org/10.1136/jitc-2020-000883

Ejemplares similares